

Boston Scientific's WallFlex® Biliary RX Stent Receives Canadian Approval for Expanded Indication

Natick, MA (August 9, 2011) – Boston Scientific Corporation's (NYSE: BSX) [WallFlex® Biliary RX Fully Covered Stent](#) has received Health Canada approval for the treatment of benign biliary strictures, which supplements its current indication for management of malignant biliary strictures (narrowing or blockage).

"Benign biliary strictures related to an injury, anastomosis or chronic pancreatitis may be challenging to resolve," said André Roy, M.D., FRCSC, Director of the Liver Transplantation Program at Hôpital Saint-Luc du Centre Hospitalier de l'Université de Montréal. "The WallFlex Stent incorporates the latest innovations in self-expanding metal stent technology and may provide significant benefits as a less-invasive alternative to surgery in these patients."

"Current management of benign biliary strictures typically includes repeated dilation with balloons and plastic stents, however, this new approval allows me to offer a one-step alternative, which may help to reduce the number of procedures my patients must undergo, while providing the best possible care and containing costs," said Paul Kortan, M.D., Gastroenterologist at St. Michaels Hospital in Toronto.

The WallFlex Biliary RX Stent is constructed of braided, Platinol™ (platinum-cored Nitinol) wire and features three key attributes: radial force to help maintain duct patency and resist migration, flexibility to aid in conforming to tortuous anatomies and full-length radiopacity to enhance stent visibility under fluoroscopy. The WallFlex Biliary RX family of stents is available in fully covered, partially covered and uncovered versions. The covered stents have a silicone polymer Permalume® coating designed to reduce the potential for tumor/tissue ingrowth, and an integrated retrieval loop for removing or repositioning the stent in the event of incorrect placement during the initial procedure or for removal up to 12 months following initial placement in benign strictures.

"The WallFlex Biliary RX Stent leverages existing Boston Scientific technologies, while advancing performance with new features based on physician feedback," said David Pierce, President of Boston Scientific's Endoscopy Division. "With our full line of WallFlex Biliary, Enteral and Esophageal Stents, Boston Scientific offers the most comprehensive range of innovative treatment options to diagnose, palliate and treat patients with gastrointestinal diseases."

The complete line of WallFlex Biliary RX Stents has previously received Health Canada, CE Mark and FDA clearance for the palliative treatment of malignant biliary strictures. The WallFlex Stent is the most frequently implanted biliary metal stent in the U.S., Canada and Europe.

In the U.S., the WallFlex Biliary RX Fully Covered Stent is not approved for the treatment of benign biliary strictures. The safety and effectiveness of the WallFlex Biliary RX Stent System for use in the vascular system have not been established.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding new product launches and launch cadence, regulatory approvals, clinical trials, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or

revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT:

Erik Kopp
508-650-8660 (office)
Media Relations
Boston Scientific Corporation
erik.kopp@bsci.com

Sean Wirtjes
508-652-5305 (office)
Investor Relations
Boston Scientific Corporation
investor_relations@bsci.com

<https://news.bostonscientific.com/wallflex-biliary-stent-canada-approval-expanded-indication>